Oncimmune Signs Agreement with America’s Choice Provider Network to Expand Access to its Blood Tests for the Early Detectio...
20 December 2018 - 11:45PM
Business Wire
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialization of personalized
immunodiagnostics for the screening, detection and care of cancer,
today announced that it has entered into an agreement with
America’s Choice Provider Network (ACPN) to expand access to
Oncimmune’s simple and affordable blood tests,
EarlyCDT®—Lung and
EarlyCDT®—Liver. ACPN is an
independent, multi-specialty provider network accessed by over
1,700 payers. More than 28 million Americans and 750,000
international lives have access to ACPN’s network.
EarlyCDT—Lung is used by clinicians to assess lung
cancer risk in high-risk patients who have an indeterminate
pulmonary nodule (IPN), and is highly specific in detecting all
types of lung cancer at all stages of disease. These attributes
make the test complementary to the high sensitivity but poor
specificity of CT scanning. EarlyCDT—Liver aids in
the detection and confirmation of hepatocellular carcinoma (HCC,
liver cancer), in association with imaging, in high-risk patients
with liver lesions of all sizes.
“Our collaboration with America’s Choice Provider Network is one
of several payor and provider agreements we have recently finalized
to ensure as many people as possible in the U.S. are able to use
our EarlyCDT® tests to facilitate earlier
diagnoses,” said Marco Casarin, General Manager, Oncimmune (USA)
LLC. “Especially in lung cancer—with nearly 1.6 million Americans
having an incidentally detected nodule on the lung—a positive
EarlyCDT—Lung outcome enables quicker clinician
intervention and better patient outcomes.”
About Oncimmune®
Oncimmune is changing how clinicians, researchers and
patients view, diagnose and treat cancer. Our technology detects
evidence of the body's natural response to cancer, enabling
detection four years or more before standard
clinical diagnosis. Our tests facilitate clinical
decision-making and are complementary to diagnostic technologies,
making them valuable additions to established and new care
pathways. We partner with leading developers and distributors
to make our technology available globally.
Oncimmune launched its platform technology in 2009, followed by
its first commercial
tests, EarlyCDT®—Lung and EarlyCDT®—Liver.
To date, over 155,000 tests have been performed for patients
worldwide. EarlyCDT—Lung is being used in the
National Health Service (NHS) ECLS study of 12,210 high-risk
smokers in Scotland, which is the largest-ever randomized trial for
the early detection of lung cancer using biomarkers.
Oncimmune is headquartered in Nottingham, UK, with a CLIA lab in
Kansas, U.S. and offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit http://oncimmune.com/. Follow
us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181220005033/en/
Media:RAliance CommunicationsReba
Auslanderreba@raliancecommunications.com917-836-9308
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024